Mark Davies

Tryptamine Therapeutics Limited | Non-Executive Chairman, Non-Executive Director

Mr Davies has over 25 years of experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital. Mark specialises in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market

Companies and Roles

Company	Title	Tenure	Since
TYP Tryptamine Therapeutics Limited	Non-Executive Chairman Non-Executive Director	1yrs, 3mth	Jun 2023
NTI Neurotech International Limited	Non-Executive Director Non-Executive Chairman	5yrs, 5mth	Apr 2019

Holdings

Company	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
NTI Neurotech International Limited	30/06/24	11,793,017	N/A	N/A	N/A
TYP Tryptamine Therapeutics Limited	01/05/24	0	2,000,000	4,000,000	N/A
EX1	19/04/24	0	N/A	4,000,000	N/A

Transactions

Company	Date	Type	Amount	Price	Value	Notes
TYP Tryptamine Therapeutics Limited	01/05/24	Issued	2,000,000	$0.020	$40,000	As advised by the company
EX1	01/12/23	Issued	10,000,000	$0.011	$110,000	Issue of options
TYP Tryptamine Therapeutics Limited	01/12/23	Issued	10,000,000	$0.011	$110,000	Issue of options
NTI Neurotech International Limited	30/11/23	Buy	2,000,000	$0.038	$76,000	Exercise of options
NTI Neurotech International Limited	30/11/23	Exercise	2,000,000	$0.038	$76,000	Exercise of options

Any feedback about this profile? Contact Us

My Watchlists

Fetching your watchlist...